Scope Fluidics S.A.

Equities

SCP

PLSCPFL00018

Biotechnology & Medical Research

Market Closed - Warsaw S.E. Other stock markets 09:25:56 31/05/2024 pm IST			5-day change	1st Jan Change
170.8 ^PLN	+1.67%		-4.58%	-12.86%

2023	Scope Fluidics S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
2023	Scope Fluidics S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI

Scope Fluidics S.A. announced that it has received PLN 13.8924 million in funding from Ipopema Towarzystwo Funduszy Inwestycyjnych S.A.

December 13, 2019

Scope Fluidics S.A. (WSE:SCP) announced a private placement of 231,540 F shares at the price of PLN 60 per share for gross proceeds of PLN 13,892,400 on December 13, 2019. The transaction included participation from TOTAL Fundusz Inwestycyjny Zamkniety, a fund managed by Ipopema Towarzystwo Funduszy Inwestycyjnych S.A. Post to the transaction, the stake held by Ipopema Towarzystwo Funduszy Inwestycyjnych S.A. has increased from 18.87% to 26.25% stake in the company.

Latest news about Scope Fluidics S.A.

Scope Fluidics S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	29/11	CI
Scope Fluidics S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	02/23/02	CI
Scope Fluidics S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	30/23/30	CI
Scope Fluidics S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/22/14	CI
Scope Fluidics S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	17/22/17	CI
Bio-Rad Laboratories, Inc. agreed to acquire Curiosity Diagnostics Sp. z o.o. from Scope Fluidics S.A. for $100 million.	03/22/03	CI
Bio-Rad Laboratories, Inc. acquired Curiosity Diagnostics Sp. z o.o. from Scope Fluidics S.A. for approximately $170 million.	03/22/03	CI
Scope Fluidics S.A. Reports Earnings Results for the First Quarter Ended March 31, 2022	16/22/16	CI
Scope Fluidics S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	15/22/15	CI
Scope Fluidics S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	12/21/12	CI
An unknown buyer signed letter of intent to acquire Curiosity Diagnostics sp. z o. o. from Scope Fluidics S.A..	04/21/04	CI
Scope Fluidics S.A. Reports Earnings Results for the Second Quarter Ended June 30, 2021	13/21/13	CI
Scope Fluidics S.A. Reports Earnings Results for the First Quarter Ended March 31, 2021	14/21/14	CI
Scope Fluidics S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2020	12/21/12	CI
Scope Fluidics S.A. announced that it has received PLN 20.4664 million in funding	30/20/30	CI
Scope Fluidics S.A. announced that it has received PLN 13.8924 million in funding from Ipopema Towarzystwo Funduszy Inwestycyjnych S.A.	13/19/13	CI
TTL 1 SP Z O O acquired 7.3% stake in Scope Fluidics S.A.	04/19/04	CI

Chart Scope Fluidics S.A.

Duration

Period

More charts

Company Profile

Scope Fluidics SA is a Poland-based company engaged in the biotechnology. The Company focuses on diagnostic and med-tech solutions. It develops disposable microfluidic systems for the collection of micro-samples of blood, as well as storage of reagents for diagnostic markers. Its projects include PCR ONE system that delivers the bacterial and viral pathogen detection, and BacterOMIC system that delivers information on bacterial susceptibility to antibiotics and on the resistance mechanisms. The Company provides access to laboratories and workshops for developed projects, as well as administrative facilities and services, including financing. In addition, it cooperates with doctors, medical personnel, project managers, engineers and academics.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
SCOPE FLUIDICS S.A.	-12.86%	118M
EXACT SCIENCES CORPORATION	-38.56%	8.39B
GUARDANT HEALTH, INC.	+0.18%	3.32B
IOVANCE BIOTHERAPEUTICS, INC.	+9.29%	2.49B
BGI GENOMICS CO., LTD.	-18.21%	2.06B
VERACYTE, INC.	-24.57%	1.59B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+32.37%	1.15B
SEEGENE, INC.	-7.64%	704M
CAREDX, INC	+8.42%	678M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-29.59%	508M

Bio Diagnostics & Testing